Limitations in immune checkpoint inhibitors in treating gastric cancer

September 26, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)Подробнее

Basics of Chemotherapy and ImmunotherapyПодробнее

Keynote Lecture: Managing Side Effects of IO AgentsПодробнее

Immune checkpoint inhibitors and combination strategies for patients with gastric cancerПодробнее

Checkpoint Inhibition in GI Cancers: Recent Advances in Gastric, Esophageal, and CRCПодробнее

Checkpoint Inhibitors Under Investigation in Upper GI and Gastric CancersПодробнее

Which patients with gastric cancer can benefit most from checkpoint inhibitors?Подробнее

Immune Checkpoint Inhibitor Therapy for Locally Advanced and Early-Stage Esophageal/GEJ CancerПодробнее

Dr. He on the Potential of Immune Checkpoint Inhibitors in GI CancersПодробнее

Clinical trials investigating immunotherapy for gastric cancerПодробнее

Treating Stomach and Gastrointestinal Cancers with ImmunotherapyПодробнее

Check-Point Inhibitors in Esophageal and Gastric Cancer: When and for Whom?Подробнее

Cancer Immune Checkpoint InhibitorsПодробнее

Checkpoint Inhibitors: Emerging Role in GE CancerПодробнее

Dr. Janjigian on Immunotherapy Combinations in Gastric CancerПодробнее

The Future of Immune Checkpoint Inhibition in Gastric and Esophageal CancersПодробнее

Treating patients with gastric cancer with immunotherapy: who will benefit?Подробнее

Overcoming resistance to immunotherapy as first-line therapy in gastric cancerПодробнее

Introduction to Immune Checkpoint Inhibitor (ICI) ImmunotherapyПодробнее

Gastric Cancer: Frontline Checkpoint Inhibitor TrialsПодробнее

Immune Checkpoint InhibitorsПодробнее

Advances in HER2-targeted therapies for gastric cancerПодробнее